Risk of Second Primary Neoplasms of the Central Nervous System

Elisa K Liu; Cheongeun Oh; Douglas Kondziolka; Erik P Sulman

doi:10.1016/j.adro.2022.100969

Risk of Second Primary Neoplasms of the Central Nervous System

Adv Radiat Oncol. 2022 Apr 18;7(4):100969. doi: 10.1016/j.adro.2022.100969. eCollection 2022 Jul-Aug.

Authors

Elisa K Liu¹, Cheongeun Oh^{2

3}, Douglas Kondziolka^{1

4}, Erik P Sulman^{1

5}

Affiliations

¹ Departments of Radiation Oncology, New York University Grossman School of Medicine, New York, New York.
² Departments of Population Health, New York University Grossman School of Medicine, New York, New York.
³ Departments of Environmental Medicine, New York University Grossman School of Medicine, New York, New York.
⁴ Departments of Neurosurgery, New York University Grossman School of Medicine, New York, New York.
⁵ Brain and Spine Tumor Center, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York.

Abstract

Purpose: Second primary (SP) neoplasms of the central nervous system (CNS) among cancer survivors are devastating but poorly understood processes. The absolute risk, or true incidence, of developing an SP CNS tumor among cancer survivors is not well characterized.

Methods and materials: Patients diagnosed with cancer between 1975 and 2016 were queried using the Surveillance, Epidemiology, and End Results Program. Cumulative incidence rates (CIRs) were estimated using competitive risk analysis. The effects of covariates were assessed using multivariate competitive risk regression.

Results: More than 3.8 million patient records were extracted. The absolute risk of developing an SP CNS neoplasm at 25 years was highest among long-term survivors of CNS cancers (CIR, 6.6%). Cranial radiation increased the incidence of SP tumors in pediatric patients (25-year CIR, 5.7% vs 1.1%; P = .0012) but not adults (25-year CIR, 5.8% vs 5.0%; P = .66). Multivariate cumulative risk regression identified radiation among pediatric patients as the greatest risk for an increased CIR (subdistribution hazard ratio, 2.50; 95% CI, 1.86-3.38; P = 2e-9). Meningiomas (42.9% vs 24.1%; P = 2e-7) and glioblastomas (20.5% vs 14.5%; P = .046) represented a greater proportion of the SP CNS tumors in those who received cranial irradiation. The median age of an SP diagnosis was decreased among those who received prior radiation (41 years [interquartile range (IQR), 30-65 years] vs 49 years [IQR, 30-65 years]; P = 7e-5).

Conclusions: The risk of developing a second primary CNS neoplasm is elevated in patients with a prior CNS cancer independent of treatment history. The association between cranial radiation therapy and risk for subsequent cancers may be limited to the pediatric population.